- Home
- CLYM vs CPIX Comparison
CLYM vs CPIX Comparison
Compare CLYM & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- CPIX
- Stock Information
- Founded
- CLYM 2018
- CPIX 1999
- Country
- CLYM United States
- CPIX United States
- Employees
- CLYM N/A
- CPIX N/A
- Industry
- CLYM
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- CPIX Health Care
- Exchange
- CLYM NYSE
- CPIX Nasdaq
- Market Cap
- CLYM 83.1M
- CPIX 68.7M
- IPO Year
- CLYM 2021
- CPIX 2009
- Fundamental
- Price
- CLYM $1.19
- CPIX $4.70
- Analyst Decision
- CLYM
- CPIX
- Analyst Count
- CLYM 0
- CPIX 0
- Target Price
- CLYM N/A
- CPIX N/A
- AVG Volume (30 Days)
- CLYM 125.8K
- CPIX 21.7K
- Earning Date
- CLYM 05-19-2025
- CPIX 05-06-2025
- Dividend Yield
- CLYM N/A
- CPIX N/A
- EPS Growth
- CLYM N/A
- CPIX N/A
- EPS
- CLYM N/A
- CPIX N/A
- Revenue
- CLYM N/A
- CPIX $41,083,299.00
- Revenue This Year
- CLYM N/A
- CPIX N/A
- Revenue Next Year
- CLYM N/A
- CPIX N/A
- P/E Ratio
- CLYM N/A
- CPIX N/A
- Revenue Growth
- CLYM N/A
- CPIX 5.82
- 52 Week Low
- CLYM $1.05
- CPIX $1.04
- 52 Week High
- CLYM $10.23
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- CPIX 52.45
- Support Level
- CLYM N/A
- CPIX $4.32
- Resistance Level
- CLYM N/A
- CPIX $4.86
- Average True Range (ATR)
- CLYM 0.00
- CPIX 0.34
- MACD
- CLYM 0.00
- CPIX -0.02
- Stochastic Oscillator
- CLYM 0.00
- CPIX 36.89
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.